Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Myeloid, Acute
  • Protein Kinase Inhibitors
  • Staurosporine
  • fms-Like Tyrosine Kinase 3

abstract

  • The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261 .).

publication date

  • August 3, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1614359

PubMed ID

  • 28644114

Additional Document Info

start page

  • 454

end page

  • 464

volume

  • 377

number

  • 5